(MENAFNEditorial)
While Singapore's small population will limit the pharmaceutical market's overall growth potential the government's commitment to healthcare as well as the ageing population will boost consumption of pharmaceuticals over the long term. In addition the impending launch of the Association of South East Asian Nations Community in 2015 will increase Singapore's attractiveness to foreign pharmaceutical firms.
Headline Expenditure Projections
* Pharmaceuticals : SGD990mn (USD790mn) in 2013 to SGD1.04bn (USD830mn) in 2014; +5.5% in local currency terms and +5.0% in US dollar terms. Forecast unchanged from Q 3 14.
* Healthcare: SGD17.78bn (USD14.21bn) in 2013 to SGD19.33bn (USD15.38bn) in 2014; +8.7% in local currency terms and +8.3% in US dollar terms. Forecast slightly downgraded from Q314.
Risk/Reward Ratings
Singapore's Pharmaceutical Risk/Reward Rating (RRR) score for Q414 is 62.1 out of the maximum 100 under our newly improved RRR system. The country scored above average for the majority of indicators and sub-indicators including sector value growth pensionable population and overall economic and political landscape. Consequently with this high score Singapore is ranked just slightly below other developed countries like Japan Australia and South Korea behind the highly attractive emerging Chinese market and also behind Taiwan and Hong Kong.
Full Report Details at
- http://www.fastmr.com/prod/872688_singapore_pharmaceuticals_healthcare_report_q4.aspx?afid=101
Key Trends And Developments
* In June 2014 the Singaporean government stated that it supports the MediShield Life Review Committee's proposals to increase claim limits and lower co-insurance particularly for the largest medical bills. As per the recommendations made by the review committee Singaporean citizens will have to pay an additional 30% in premiums to the proposed MediShield Life universal healthcare insurance scheme for 10 years. The committee also suggested moves such as the removal of the lifetime claim limit of SGD300000 (USD239000) and for the government to cover most of the...
The Singapore Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Singapore Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Singaporean pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Singapore to test other views - a key input for successful budgeting and strategic business planning in the Singaporean pharmaceutical and healthcare market.
* Target business opportunities and risks in the Singaporean pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Singapore.
* Assess the activities strategy and market position of your competitors partners and clients via our Company Profiles (inc. SWOTs KPIs and latest activity) and Competitive Landscape Tables.
Coverage
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis and taken together with BMI's political economic and business environment SWOTS it gives a complete overview of market climate.
Market Summary
Snapshot of key market characteristics including total size of pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape.
Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as an analysis of the overall regulatory burden.
Industry Developments
Focus on government healthcare reforms epidemiological trends company M&As product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions plus analysis of key downside risks to the main forecast including:
Healthcare: Total healthcare expenditure (US$bn) healthcare expenditure (% of GDP) healthcare expenditure per capita (US$) hospital beds (per `000 population) doctors (per `000 population) birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn) drug expenditure (% of GDP) drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn) prescription sales (% of total sales) sales broken down by 14 therapeutic areas (cardiovascular anti-infectives etc.)
Generic drug market: Generic product sales (US$bn) generic sales (% of total sales)
OTC drug market: OTC sales (US$bn) OTC sales (% of total sales) sales broken down by product types (analgesics skin treatments vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn) medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against US$ government expenditure external debt.
Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.